Drug Trial Radar · NCT06671392
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Feb 24, 2025
Primary completion
Feb 5, 2026
Study completion Feb 5, 2026
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential Hypertension Inadequately Controlled with DWC202405
Conditions
- Essential Hypertension
Interventions
DWC202405Drug
5/20mg, 1 tablet, Oral, Once a day
DWC202405, DWC202314Drug
5/20mg + 1.5mg, 1 tablet, Oral, Once a day
DWC202405, DWC202314PDrug
5/20mg + 1.5mg, 1 tablet, Oral, Once a day
DWC202313, DWC202314Drug
10/40mg + 1.5mg, 1 tablet, Oral, Once a day
DWC202313, DWC202314PDrug
10/40mg + 1.5mg, 1 tablet, Oral, Once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baselineTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University ANAM Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.